Previous 10 | Next 10 |
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced its participa...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced its participa...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provides updates on rec...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced its participa...
These Former Penny Stocks Are Turning Heads In The Stock Market This Year When it comes to trading penny stocks, you come across plenty of success stories. These typically involve big moves within short periods of time and huge windfalls for traders. They also usually entail a quick dro...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that it is se...
Poster published at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting shows the final 5 year safety data from the Phase IIb breast cancer clinical trial. Final safety conclusions are that GP2 immunotherapy is well tolerated and that no serious adverse events rel...
Texas-based biotech Greenwich Life Sciences (NASDAQ: GLSI) is currently developing immunotherapy for use against certain types of breast cancer. Founded in 2006, the company was actually 2020's top-performing IPO, appearing on the market at $5.75 in September and hitting a low of $3...
Previously led partnering transactions and strategic analyses for multiple companies, including Roche, Pfizer, and Novartis Dr. Fischette will focus on out-licensing the Company’s lead drug candidate for recurring breast cancer, GP2, and building a clinical pipeline to comp...
Insider buying increased significantly last week. Notable Insider Buys: Landec Corporation, Super League Gaming, Inc., Cyclo Therapeutics, Inc., Greenwich LifeSciences, Inc., and Hudson Global, Inc. Notable Insider Sells: Ulta Beauty, Inc., Facebook, Inc., Fidelity National Financ...
News, Short Squeeze, Breakout and More Instantly...
Greenwich LifeSciences Inc. Company Name:
GLSI Stock Symbol:
NASDAQ Market:
Greenwich LifeSciences Inc. Website:
2024-07-11 21:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, tod...
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer r...